| Esther Paula Soundar, MD | |
|
550 University Blvd Rm 3565c, Indianapolis, IN 46202-5149 | |
| (317) 948-7728 | |
| Not Available |
| Full Name | Esther Paula Soundar |
|---|---|
| Gender | Female |
| Speciality | Pathology |
| Experience | 35 Years |
| Location | 550 University Blvd Rm 3565c, Indianapolis, Indiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861837320 | NPI | - | NPPES |
| 1447758438 | Medicaid | IN | |
| 1891927026 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZB0001X | Pathology - Blood Banking & Transfusion Medicine | 01079014A (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Indiana University Health | Indianapolis, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Family Physicians, Inc. | 7911992797 | 424 |
News Archive
In the wake of multiple state bans on caffeinated alcoholic beverages (CABs) and an FDA warning to four companies to remove their products from the marketplace, an article published online today in the American Journal of Preventive Medicine delineates the scope of the public health problem and suggests areas of research that might help address it.
Since the emergence in December 2019 in Wuhan, China, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide via transmission among close human contacts. Early on, several public health interventions were implemented in Wuhan city and Hubei Province, including lockdowns, social distancing, traffic restrictions, stay-at-home policies, face mask requirements, building temporary hospitals, and centralized quarantine. There were 50,355 confirmed cases of SARS-CoV-2 infection in Wuhan as of 28 January 2021.
Among patients with oral anticoagulation-associated intracerebral hemorrhage (bleeding within the brain), reversal of international normalized ratio (INR; a measure used to determine the clotting tendency of blood while on medication) below a certain level within 4 hours and systolic blood pressure less than 160 mm Hg at 4 hours were associated with lower rates of hematoma (a localized swelling filled with blood) enlargement, and resumption of anticoagulant therapy was associated with a lower risk of ischemic events without increased bleeding complications, according to a study in the February 24 issue of JAMA.
Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has executed an agreement with The Research Foundation of the State University of New York (SUNY), acting for and on behalf of Binghamton University (Binghamton, NY).
Frost & Sullivan is pleased to announce the award of its prestigious 2010 European Influenza Vaccines Technology Innovation Award to BiondVax Pharmaceuticals for their breakthrough work on a universal influenza vaccine. This vaccine, the Multimeric-001, is designed to provide multi-season and multi-strain protection against most influenza virus strains, including both seasonal and pandemic strains, and has the potential to eliminate the need for annual flu vaccination. BiondVax is entering Phase II clinical trials for the development of the Multimeric-001 universal influenza vaccine.
› Verified 3 days ago
| Entity Name | University Family Physicians, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043275787 PECOS PAC ID: 7911992797 Enrollment ID: O20040420000393 |
News Archive
In the wake of multiple state bans on caffeinated alcoholic beverages (CABs) and an FDA warning to four companies to remove their products from the marketplace, an article published online today in the American Journal of Preventive Medicine delineates the scope of the public health problem and suggests areas of research that might help address it.
Since the emergence in December 2019 in Wuhan, China, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide via transmission among close human contacts. Early on, several public health interventions were implemented in Wuhan city and Hubei Province, including lockdowns, social distancing, traffic restrictions, stay-at-home policies, face mask requirements, building temporary hospitals, and centralized quarantine. There were 50,355 confirmed cases of SARS-CoV-2 infection in Wuhan as of 28 January 2021.
Among patients with oral anticoagulation-associated intracerebral hemorrhage (bleeding within the brain), reversal of international normalized ratio (INR; a measure used to determine the clotting tendency of blood while on medication) below a certain level within 4 hours and systolic blood pressure less than 160 mm Hg at 4 hours were associated with lower rates of hematoma (a localized swelling filled with blood) enlargement, and resumption of anticoagulant therapy was associated with a lower risk of ischemic events without increased bleeding complications, according to a study in the February 24 issue of JAMA.
Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has executed an agreement with The Research Foundation of the State University of New York (SUNY), acting for and on behalf of Binghamton University (Binghamton, NY).
Frost & Sullivan is pleased to announce the award of its prestigious 2010 European Influenza Vaccines Technology Innovation Award to BiondVax Pharmaceuticals for their breakthrough work on a universal influenza vaccine. This vaccine, the Multimeric-001, is designed to provide multi-season and multi-strain protection against most influenza virus strains, including both seasonal and pandemic strains, and has the potential to eliminate the need for annual flu vaccination. BiondVax is entering Phase II clinical trials for the development of the Multimeric-001 universal influenza vaccine.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Esther Paula Soundar, MD 5212 Knollton Rd, Indianapolis, IN 46228-2284 Ph: (832) 622-2145 | Esther Paula Soundar, MD 550 University Blvd Rm 3565c, Indianapolis, IN 46202-5149 Ph: (317) 948-7728 |
News Archive
In the wake of multiple state bans on caffeinated alcoholic beverages (CABs) and an FDA warning to four companies to remove their products from the marketplace, an article published online today in the American Journal of Preventive Medicine delineates the scope of the public health problem and suggests areas of research that might help address it.
Since the emergence in December 2019 in Wuhan, China, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide via transmission among close human contacts. Early on, several public health interventions were implemented in Wuhan city and Hubei Province, including lockdowns, social distancing, traffic restrictions, stay-at-home policies, face mask requirements, building temporary hospitals, and centralized quarantine. There were 50,355 confirmed cases of SARS-CoV-2 infection in Wuhan as of 28 January 2021.
Among patients with oral anticoagulation-associated intracerebral hemorrhage (bleeding within the brain), reversal of international normalized ratio (INR; a measure used to determine the clotting tendency of blood while on medication) below a certain level within 4 hours and systolic blood pressure less than 160 mm Hg at 4 hours were associated with lower rates of hematoma (a localized swelling filled with blood) enlargement, and resumption of anticoagulant therapy was associated with a lower risk of ischemic events without increased bleeding complications, according to a study in the February 24 issue of JAMA.
Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has executed an agreement with The Research Foundation of the State University of New York (SUNY), acting for and on behalf of Binghamton University (Binghamton, NY).
Frost & Sullivan is pleased to announce the award of its prestigious 2010 European Influenza Vaccines Technology Innovation Award to BiondVax Pharmaceuticals for their breakthrough work on a universal influenza vaccine. This vaccine, the Multimeric-001, is designed to provide multi-season and multi-strain protection against most influenza virus strains, including both seasonal and pandemic strains, and has the potential to eliminate the need for annual flu vaccination. BiondVax is entering Phase II clinical trials for the development of the Multimeric-001 universal influenza vaccine.
› Verified 3 days ago
Dr. Manan Chandrakant Patel, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 2560 N. Shadeland Avenue, Suite A, Indianapolis, IN 46219 Phone: 317-275-8072 Fax: 317-275-8124 | |
Dr. John M. Oscherwitz, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 2560 N. Shadeland Ave., Suite A, Indianapolis, IN 46219 Phone: 317-275-8072 Fax: 317-275-8018 | |
Harvey Cramer, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 720 Eskenazi Ave, Indianapolis, IN 46202 Phone: 317-788-0000 | |
Dr. Craig M. Novy, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 2560 N. Shadeland Ave., Suite A, Indianapolis, IN 46219 Phone: 317-275-8072 Fax: 317-275-8018 | |
Darin L Wolfe, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 635 Barnhill Dr # A128, Indianapolis, IN 46202 Phone: 317-274-4806 | |
Muhammad Ahmad, MD Pathology Medicare: Medicare Enrolled Practice Location: 1701 N Senate Blvd, Indianapolis, IN 46202 Phone: 317-491-6000 Fax: 317-491-6534 | |
Carina Anja Dehner, MD, PHD Pathology Medicare: May Accept Medicare Assignments Practice Location: 1701 N Senate Blvd, Indianapolis, IN 46202 Phone: 317-491-6000 Fax: 317-491-6534 |